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ABSTRACT
Background and aims: The effect of adiponectin on
colorectal carcinogenesis has been proposed but not fully
investigated. We investigated the effect of adiponectin
deficiency on the development of colorectal cancer.
Methods: We generated three types of gene-deficient
mice (adiponectin-deficient, adiponectin receptor 1-
deficient, and adiponectin receptor 2-deficient) and
investigated chemical-induced colon polyp formation and
cell proliferation in colon epithelium. Western blot analysis
was performed to elucidate the mechanism which
affected colorectal carcinogenesis by adiponectin defi-
ciency.
Results: The numbers of colon polyps were significantly
increased in adiponectin-deficient mice compared with
wild-type mice fed a high-fat diet. However, no difference
was observed between wild-type and adiponectin-
deficient mice fed a basal diet. A significant increase in
cell proliferative activity was also observed in the colonic
epithelium of the adiponectin-deficient mice when
compared with wild-type mice fed a high-fat diet;
however, no difference was observed between wild-type
and adiponectin-deficient mice fed a basal diet. Similarly,
an increase in epithelial cell proliferation was observed in
adiponectin receptor 1-deficient mice, but not in
adiponectin receptor 2-deficient mice. Western blot
analysis revealed activation of mammalian target of
rapamycin, p70 S6 kinase, S6 protein and inactivation of
AMP-activated protein kinase in the colon epithelium of
adiponectin-deficient mice fed with high-fat diet.
Conclusions: Adiponectin suppresses colonic epithelial
proliferation via inhibition of the mammalian target of the
rapamycin pathway under a high-fat diet, but not under a
basal diet. These studies indicate a novel mechanism of
suppression of colorectal carcinogenesis induced by a
Western-style high-fat diet.
Adipose tissue produces and secretes several bioac-
tive substances
12 known as adipocytokines,
3 and
obesity is an important risk factor for many human
diseases, including colorectal cancer and diabetes
mellitus.
45Several case–control studies have shown
that high-fat diets may promote the development of
colorectal cancer,
6 and the results of animal experi-
ments suggest the existence of a link between fat
intake and colorectal cancer
7. Adiponectin is mainly
secreted by adipocytes
8 and is a key hormone
responsible for insulin sensitisation.
91 0While adipo-
nectin protein is abundantly found in the plasma of
healthy human subjects,
11 adiponectin mRNA levels
in the adipose tissue and plasma are dramatically
decreased in patients with obesity and/or type 2
diabetes mellitus.
12 13 Because both obesity and type
2d i a b e t e sh a v eb e e nr e p o r t e dt ob ea s s o c i a t e dw i t h
an elevated risk of colorectal cancer,
14–16 we hypothe-
sised that the plasma level of adiponectin may be
related to the risk of colorectal cancer.
Several contradictory results have been reported
from human clinical studies on the relationship
between the plasma levels of adiponectin and the
risk of colorectal cancer.
17 18 While some clinical
studies have been conducted in humans, no studies
investigating the relationship between the plasma
levels of adiponectin and the risk of colorectal
cancer have been reported in animal models.
Therefore, the mechanism underlying the promo-
tion of colorectal carcinogenesis by adiponectin
deficiency still remains unclear.
It is now well known that the adiponectin
receptor exists in two isoforms: adiponectin
receptor 1 (AdipoR1), which is abundantly
expressed in the skeletal muscle; and adiponectin
receptor 2 (AdipoR2), which is predominantly
expressed in the liver.
19 These receptors mediate
the enhanced activation of AMP-activated protein
kinase (AMPK) and the peroxisome proliferator-
activated receptor a (PPARa), as well as the
increase in fatty-acid oxidation and glucose uptake
induced by adiponectin.
20 21
Recently, involvement of the AMPK/mamma-
lian target of rapamycin (mTOR) pathway in the
development of various types of cancer has
attracted attention.
22–24 The important role of
mTOR in mammalian cells is related to its control
of mRNA translation. The targets for mTOR
signalling are proteins involved in controlling the
translational machinery, including the ribosomal
protein S6 kinases and S6 proteins that regulate the
initiation and elongation phases of translation.
25 26
With regard to the upstream control, mTOR is
regulated by signalling pathways linked to several
oncoproteins or tumour suppressors, including
AMP-activated protein kinase (AMPK).
23 27 mTOR
is located at the intersection of major signalling
pathways and is believed to be capable of integrat-
ing a large panel of stress signals, including
nutrient deprivation, energy depletion, and oxida-
tive or hypoxic stresses. In particular, AMPK
activation has been reported to directly inhibit
mTOR
28 and suppress cell proliferation.
Using adiponectin-deficient mice (KO) we there-
fore investigated whether adiponectin deficiency
might promote the development of colorectal
cancer, and examined the involvement of the
AMPK/mTOR pathway in the effect of adiponec-
tin on colon carcinogenesis.
Colorectal cancer
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Animal models
All mice were treated humanely in accordance with the
National Institutes of Health and AERI-BBRI Animal Care
and Use Committee guidelines. Adiponectin (ACRP30 or
AdipoQ)-deficient (ACRP302/2) mice (KO mice) and adipo-
nectin receptor 1 or 2-deficient mice (AdipoR12/2 or
AdipoR22/2) were generated by our group as described
previously.
21 We performed the experiments in this study using
littermate mice backcrossed to C57Bl/6 for 10 generations.
The animals were fed a basal diet or a high-fat diet until the
end of the study. The composition of both diets is listed in
supplementary table 1. Three to five mice were housed per
metallic cage with sterilised softwood chips as bedding, in a
barrier-sustained animal room air-conditioned at 24 (SD 2)uC
and 55% humidity, under a 12 h light–dark cycle.
Induction of colon polyps
Azoxymethane (AOM) was purchased from Sigma (St. Louis,
Missouri, USA). Mice (6 weeks old) were divided into four
groups: (1) WT mice fed the basal diet (n=10), (2) KO mice fed
the basal diet (n=10), (3) WT mice fed the high-fat diet
(n=10), and (4) KO mice fed the high-fat diet (n=10). Mice
were injected intraperitoneally with 10 mg/kg of AOM once a
week for 6 weeks and sacrificed at 20 weeks following initiation
of AOM injection to evaluate the difference in the extent of
polyp formation between the KO and WT mice (supplementary
fig 1A).
Induction of aberrant crypt foci
Mice (6 weeks old) were divided into four groups: (1) WT mice
fed the basal diet (n=12 mice), (2) KO mice fed the basal diet
(n=11), (3) WT mice fed the high-fat diet (n=11), and (4) KO
mice fed the high-fat diet (n=11). Mice were given two weekly
intraperitoneal injections of 10 mg/kg of AOM and sacrificed at
6 weeks following initiation of AOM injection (supplementary
fig 1B). The protocol of the 2-amino-1-methyl-6-phenylimidazo-
[4,5-b]pyridine (PhIP)-induced aberrant crypt foci (ACF) model
is shown in supplementary fig 2A.
29
Effect of the AMP kinase activator and mTOR inhibitor on colon
carcinogenesis
The AMP kinase activator 5-aminoimidazole-4-carboxamide-l-b-
D-ribofuranoside (AICAR) and the mTOR inhibitor rapamycin
were purchased from BIOMOL (Plymouth Meeting, PA, USA).
WT and KO mice (6 weeks old) were intraperitoneally injected
with AICAR (0.1 mg/kg/day), rapamycin (0.2, 0.4, 0.8 mg/kg)
or vehicle (saline) until the end of the experiment. The mice in
each group were fed the high-fat diet and received AOM
injections according to the ACF protocol.
Table 1 Histological findings of azoxymethane-induced colon polyps in
adiponectin-deficient (KO) mice and wild-type (WT) mice receiving a
high-fat diet
Experimental group Adenocarcinoma Adenoma Total
WT (n=10) 15 (42%) 21 (58%) 36 (100%)
KO (n=10) 51 (60%) 34 (40%) 85 (100%)
Figure 1 Promotion of colon polyp
formation in adiponectin-deficient (KO)
mice under the high-fat diet condition.
(A) Upper panel: Macroscopic findings of
colon polyp in wild-type (WT) and KO
littermate mice under the high-fat diet
condition at 20 weeks following initiation
of azoxymethane (AOM) injection. Lower
panel: Number and diameter of polyps per
mouse in the high-fat diet groups. Each
column represents the mean (with the
SEM), *p,0.05. (B) Survival rate of the
WT and KO littermates under the high-fat
diet condition. The survival rate of the WT
mice (solid line) was significantly higher
than that of the KO mice (broken line)
under the high-fat diet condition. More
than half of the KO mice died by the end
of the study, while only two of the WT
mice died. (C) Invasive polyps in the
colons obtained from the KO mice under
the high-fat diet condition. Haematoxylin
and eosin staining (upper and middle
panels) and Elastica van Gieson staining
(EVG stain, lower panel) were performed
using samples isolated from three
individual animals.
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The entire colon was removed and fixed in 10% neutralised
formalin and the numbers of polyps, ACF and aberrant crypts
(ACs) were counted as described previously.
30 To facilitate
counting, the colons were stained with 0.2% methylene blue
solution and observed by stereomicroscopy. After being
counted, they were removed and embedded in paraffin blocks
according to standard procedures. Paraffin sections were then
prepared at 3.0 mm thickness, stained with hematoxylin & eosin
and Elastica van Gieson staining for a detection of submucosal
invasion, and subjected to histological analysis.
Analysis of the survival rate
In the polyp induction experiment, both the KO (n=11) and
WT (n=12) mouse groups were continuously observed for
45 weeks. Survival curves were drawn using the Kaplan–Meier
method and analysed using the log-rank test.
Assay for assessment of the proliferative activity of the colon
epithelial cells
We evaluated the bromodeoxyuridine (BrdU) and the prolifer-
ating cell nuclear antigen (PCNA) labelling indices to determine
the proliferative activity of the colon epithelial cells. BrdU (BD
Biosciences, New Jersey, USA) was diluted in phosphate-
buffered saline at 1 mg/ml and administered intraperitoneally
at a dose of 50 mg/kg, 1 h prior to the sacrifice of the mice.
Immunohistochemical detection of BrdU was performed using a
commercial kit (BD Biosciences) and a PCNA detection kit
(Zymed Laboratories, South San Francisco, California, USA)
was used for PCNA detection. The BrdU and PCNA labelling
indices were expressed as the ratio of the number of positively
stained nuclei to the total number of nuclei counted in the
crypts of the colon. The criteria for selecting the crypts included
the presence of a clearly visible and continuous cell column on
each side of the crypt. Twenty crypts were evaluated each
mouse.
Immunoblotting
The extracted protein was separated by sodium dodecyl
sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and the
separated proteins were transferred to a polyvinylidene difluor-
ide (PVDF) membrane (Amersham, London, UK). The mem-
branes were probed with primary antibodies specific for
adiponectin receptor 1, adiponectin receptor 2 (Santa Cruz
Biotech, California, USA), phospho-AMPK, AMPK, phospho-
mTOR, mTOR, phospho-S6K, S6K, phospho-S6 protein, S6
protein (Cell Signaling Technology, Danvers, Massachusetts,
USA) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
(Trevigen, Gaithersburg, Maryland, USA). Horseradish-perox-
idase-conjugated secondary antibodies and the enhanced che-
miluminescence (ECL) detection kit (Amersham) were used for
the detection of specific proteins.
Statistical analysis
Statistical analyses for the number of ACF, number of colon
polyps, BrdU labelling index and PCNA labelling index were
conducted using the Mann–Whitney test. The results for
western blot analysis were obtained using the Student t test.
Values of p,0.05 were regarded as denoting statistical
significance.
RESULTS
Promotion of colon polyp formation and lower survival rate in
adiponectin-deficient mice under the high-fat diet
The number of polyps in the KO mice was significantly higher
than that in the WT mice under the high-fat diet (fig 1A), while
there was no difference in the total number of polyps between
the WT and KO mice under the basal diet (supplementary fig 3).
The sum of the diameter of the polyps per mouse was also
measured and similar results were obtained. Table 1 shows
histological findings of polyps in mice under high-fat diet. We
also observed the survival rate of the WT and KO mice under
the high-fat diet condition in the AOM model, and there was a
significantly higher survival rate in the WT mice than in the KO
mice. While more than half of the KO mice were dead by the
end of the study, only two WT mice died (fig 1B).
Interestingly, invasion by malignant cells was observed in
parts of the polyps exclusively in the KO mice under the high-
fat diet, and the malignant cells were found to have destroyed
the muscularis mucosae and invaded the submucosal layer in
Figure 2 Enhancement of the formation
of aberrant crypt foci (ACF) in
adiponectin-deficient (KO) mice under the
high-fat diet condition. (A,B) Average
number of ACF (A) and aberrant crypts
(ACs) (B) in the two groups, wild-type
(WT) and KO littermate mice, under the
high-fat condition, respectively. Each
column represents the mean (with the
SEM), *p,0.05, **p,0.01.
(C) Stereomicroscopic observations of
ACF in colon tissue from each group. The
samples were stained with 0.2%
methylene blue. (D) Representative
haematoxylin and eosin staining of ACF in
WT and KO mice under the high-fat diet
condition.
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observed in the WT mice. At the end of experiment, the body
weight in KO mice was decreased compared to WT mice under
the high-fat diet (supplementary fig 4A,B).
Enhanced formation of aberrant crypt foci in adiponectin-
deficient mice under the high-fat diet
To investigate the effect of adiponectin in suppressing colon
carcinogenesis under the high-fat diet, we analysed colon
specimens for the formation of ACF, defined as clusters of
aberrant crypts, as a marker of the early stage of colorectal
carcinogenesis.
31 32 Although there were no significant differ-
ences in the total number of ACF and ACs between the WT and
KO littermates mice under the basal diet (data not shown), the
numbers of ACF and ACs in the KO mice were significantly
higher than those in the WT littermates under the high-fat diet
(fig 2A,B). The macroscopic and microscopic characteristics of
the ACF in the WT and KO mice under the high-fat diet
condition are shown in fig 2C,D; no morphological differences
of the ACF were observed between the WT and the KO mice.
The differences in the body weight (supplementary fig 4C,D)
and the serum levels of adiponectin, glucose, insulin, lipids, and
tumour necrosis factor a between the WT and the KO mice are
shown in supplementary table 2. In agreement with previous
metabolic studies of adiponectin-deficient mice,
33 there were no
differences between the two groups under the high-fat diet. To
confirm the protective role of adiponectin in colorectal
carcinogenesis, the food-borne carcinogen PhIP was used as a
second model of colon carcinogenesis in mice fed a high-fat diet.
Similar results to those obtained using the AOM-induced
carcinogenesis model was obtained (supplementary fig 2).
Increase in cell proliferative activity in adiponectin-deficient
mice under the high-fat diet condition
We investigated the proliferative activity of the colon epithe-
lium by determining the BrdU and PCNA labelling indices. Both
indices were increased in the KO mice as compared with their
WT littermates under the high-fat diet (fig 3A–D). On the other
hand, there was no difference under the basal diet (data not
shown). Moreover, we examined both indices in colon polyps
under the high-fat diet but there was no difference between WT
and KO mice (supplementary fig 5).
Adiponectin ameliorates epithelial cell hyper-proliferation in
adiponectin-deficient mice under the high-fat diet condition
We administered recombinant adiponectin via an intraperito-
neal injection to KO mice in comparison to their WT littermates
under the high-fat diet condition. Globular domain adiponectin
Figure 3 Increase in the colonic
epithelial cell proliferative activity in
adiponectin-deficient (KO) mice under the
high-fat diet condition. (A,B) Average
bromodeoxyuridine (BrdU) labelling index
(A) and proliferating cell nuclear antigen
(PCNA) labelling index (B) in each group
in the aberrant crypt foci (ACF) formation
experiment. BrdU was administered
intraperitoneally 1 h prior to the sacrifice
of the animals. Both indices were
expressed as the percentage of positively
stained nuclei out of the total number of
nuclei counted in the crypts of the colon.
Each bar represents the mean (with the
SEM), *p,0.05, **p,0.01.
(C,D) Representative
immunohistochemical staining for BrdU
(C) and PCNA (D) in each group.
(E,F) Wild-type (WT) mice and KO
littermate mice fed the high-fat diet were
injected intraperitoneally with 50 mg/body
recombinant full-length adiponectin
(f-Adipo) or 5 mg/body recombinant
globular adiponectin domain (g-Adipo) or
only vehicle every other day for 6 weeks
in an ACF experiment. Adiponectin
ameliorates the epithelial cell
hyperproliferation in the KO mice under
the high-fat diet condition (E). The same
effect was observed on the suppression
of ACF formation (F).
Colorectal cancer
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activity of colon epithelial cells than full-length adiponectin
under the high-fat diet (fig 3E). The same effect was observed
on the suppression of ACF formation (fig 3F).
The increase in cell proliferative activity in adiponectin receptor
1-deficient mice under the high-fat diet
By using western blot analyses we investigated whether
adiponectin receptors are expressed in the colon epithelium,
and observed that AdipoR1 was predominantly expressed in the
colon in comparison to AdipoR2 (fig 4A).
The BrdU index in the AdipoR12/2 mice was significantly
higher than in their WT littermates under the high-fat diet
(fig 4B). The numbers of ACF and ACs in the AdipoR12/2 mice
were also significantly higher than their WT littermates (fig 4D).
However, no difference in BrdU index and the number of ACF
was observed in AdipoR22/2 mice and their WT littermates
(fig 4C,E). These results suggest that the AdipoR1-mediated,
but not the AdipoR2-mediated, pathway may play an impor-
tant role in the suppressive effect of adiponectin on colorectal
carcinogenesis under the high-fat diet, not under the basal diet.
The mTOR pathway is relatively activated in the colon epithelium
of adiponectin-deficient mice in comparison to wild-type mice
under the high-fat diet
In order to clarify the mechanisms underlying the enhanced
proliferative activity of the colon epithelial cells in the presence
of adiponectin deficiency, we investigated the expression levels
of various potential target proteins in colonic specimens
prepared from the WT mice and KO mice under the high-fat
diet. The results of western blot analysis revealed that the
amounts of phosphorylated mTOR, S6 kinase and S6 protein
were significantly higher in the KO mice compared with the
WT mice under the high-fat diet (fig 5B–D). It has been reported
that adiponectin activates AMPK via AdipoR1, and AMPK is
known to suppress the mTOR pathway.
20 34 A significant
decrease in the level of phosphorylated AMPK was observed in
the KO mice compared with that in the WT mice under the
high-fat diet (fig 5A). Moreover, adiponectin administration
ameliorated activation of the AMPK/mTOR pathway in KO
mice under the high-fat diet condition (supplementary fig 6).
These results indicate that, under the high-fat diet, deficiency of
adiponectin suppresses AMPK activation, which results in
Figure 4 Expression of the adiponectin
receptors AdipoR1 and AdipoR2 in the
liver, ileum and colon, and promotion of
epithelial cell proliferation in AdipoR12/2
mice under high-fat diet condition.
(A) Westernblotanalysistoinvestigate the
expression of AdipoR1 and AdipoR2 was
performed on protein obtained from the
liver, ileum and colon. The ratio in the liver
was defined as 1.0. (B,C): Average
bromodeoxyuridine (BrdU) labelling index
oncolonepitheliumfromAdipoR12/2 and
AdipoR22/2 mice in comparison to the
wild-type (WT) littermate mice under basal
and high-fat diet condition. The increase in
the epithelial cell proliferation was
observed in AdipoR12/2 mice, but not in
AdipoR22/2 mice under the high-fat diet
condition. (D,E) Average number of
aberrant crypt foci (ACF) in AdipoR12/2
(D) and AdipoR22/2 mice (E).
GADPH, glyceraldehyde-3-phosphate
dehydrogenase.
Colorectal cancer
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proliferation. To confirm whether adiponectin actually sup-
presses the AMPK/mTOR pathway, we treated mice with the
specific AMPK activator AICAR, or the mTOR inhibitor
rapamycin. The increase of cell proliferation in the colon
epithelium was significantly suppressed by AICAR in the KO
mice under the high-fat diet, but no effect in WT mice under
high-fat diet (fig 6A,B). Similarly, ACF formation was sig-
nificantly suppressed by AICAR in the KO mice under the high-
fat diet, but not in the WT mice (fig 6C). In the KO mice under
the high-fat diet, treatment with rapamycin significantly
reduced the BrdU index in a dose dependent manner and ACF
formation (fig 6D,E). These results indicate that the activation
of the mTOR pathway may play important roles in the increase
in epithelial cell proliferation in KO mice under the high-fat diet,
and may play an important role in the promotion of colon
carcinogenesis in KO mice under the high-fat diet condition.
DISCUSSION
The existence of a relationship between high-fat diets and
colorectal cancer has been speculated for a long time, but no
definitive conclusions have been arrived at yet.
35 It has been
reported that the secretion of adiponectin from adipocytes is
suppressed in obese humans.
11 Considered together with the
knowledge that obesity is also an important risk factor for
colorectal cancer,
4 we speculated that adiponectin might
suppress the development of colorectal cancer.
We demonstrated significantly enhanced formation of polyps
and ACF in the KO mice compared with that in the WT mice
under the high-fat diet. Furthermore, an increase in proliferative
activity of colonic epithelial cells was also observed in the KO
mice under the high-fat diet, but not under the basal diet. These
results suggest that under the high-fat diet, but not under basal
diet, a deficiency of adiponectin significantly promotes the
proliferative activity of the colonic epithelial cells, and thereby
may be promoting colorectal carcinogenesis. We demonstrated
that the AdipoR1 is predominantly expressed in colon epithe-
lium. The increase in the proliferative activity of the colonic
epithelial cells and the number of ACF were observed in
AdipoR12/2 mice, not in the AdipoR22/2 mice, under high-
fat diet condition. These results suggest that the AdipoR1-
mediated, but not the AdipoR2-mediated, pathway may play an
important role in the suppressive effect of adiponectin on the
increased in epithelial cell proliferation under the high-fat diet.
We demonstrated the activation of the mTOR pathway and
inactivation of AMPK in colon epithelial cells in the KO mice
under the high-fat diet, but there was no difference under the
basal diet (data not shown). Moreover, the replacement of
adiponectin ameliorated the activated mTOR pathway by
adiponectin deficiency. AICAR, the AMPK specific activator,
suppressed the increase in epithelial cell proliferation in KO
mice, but not in WT littermates, under high-fat diet.
Furthermore, rapamycin, an mTOR inhibitor, also significantly
suppressed the increase in epithelial cell proliferation only in KO
mice under high-fat diet in a dose dependent manner,
Figure 5 Activation of the mammalian
target of rapamycin (mTOR) pathway in
adiponectin-deficient (KO) mice compared
with that in wild-type (WT) mice under
the high-fat diet condition. Western blot
analysis for phosphorylated and total
AMP-activated protein kinase (AMPK)
(A), mTOR (B), p70 S6 kinase (C) and S6
protein (D) in the colon from the WT and
KO mice under the high-fat diet condition.
Left panels: Pictures of the western
blotting. Right panels: Graphs showing
the ratios of the phosphorylated protein to
the total protein. Each column represents
the mean (with the SEM), *p,0.05.
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epithelial cell proliferation where there is a lack of adiponectin
under a high-fat diet. It has been reported that AMPK directly
inhibits mTOR.
28 Therefore we speculate that the AMPK/
mTOR pathway is a possible mechanism closely involved in the
protective effect of adiponectin in colon carcinogenesis under
the high-fat diet (supplementary fig 7). Concerning other major
pathways in the carcinogenesis, it was reported that adiponec-
tin attenuated the adenomatous polyposis coli (APC)/b-catenin
pathway,
36 and increased p53 expression
37 in different kinds of
cancer cells. p53 also suppresses the mTOR pathway through
activation of phosphatase and tensin homologue deleted on
chromosome ten (PTEN), AMPK, insulin-like growth factor-1-
binding protein 3 (IGF1-BP3) and tuberous sclerosis complex-2
(TSC-2).
38 Although the mechanism underlying the promotion
of colon carcinogenesis by a high-fat diet is still unknown, our
present data strongly suggest that plasma adiponectin derived
from adipocytes suppresses the mTOR pathway through the
activation of AMPK, resulting in suppression of the cell
proliferative activity and, thereby, suppression of colon carci-
nogenesis, under the high-fat diet. However, in the event of a
decrease in plasma adiponectin level, AMPK activity is
suppressed, resulting in the activation of mTOR and the
members downstream in the pathway, such as the p70 S6
kinase and S6 protein. We speculate that activation of the
mTOR pathway directly promotes colonic epithelial cell
proliferation and, thereby, colorectal carcinogenesis.
It has been reported that the plasma adiponectin levels are
decreased in humans under the conditions of obesity and/or
diabetes mellitus.
11 However, it was reported that plasma
levels of adiponectin in the mice are not decreased in response
to high-fat feeding for several weeks.
39 Therefore, we used
Figure 6 Suppression of epithelial cell hyper-proliferation by activation of AMP-activated protein kinase (AMPK) or by inhibition of the mammalian
target of rapamycin (mTOR) in adiponectin-deficient (KO) mice under the high-fat diet condition. Wild-type (WT) mice (6 weeks old) were injected
intraperitoneally with the AMPK activator 5-aminoimidazole-4-carboxamide-l-b-D-ribofuranoside (AICAR) (0.1 mg/kg/day), or vehicle until the end of the
experiment. Mice in the high-fat diet group were also given two weekly intraperitoneal injections of 10 mg/kg of azoxymethane (AOM). (A) Average
bromodeoxyuridine (BrdU) labelling index in the WT and KO mice treated (+) or not treated (2) with AICAR under the high fat diet condition. BrdU was
administered intraperitoneally 1 h prior to the sacrifice of the animals. Each column represents the mean (with the SEM), *p,0.05. (B) Representative
immunohistochemical staining patterns for BrdU in each group. (C) Average number of aberrant crypt foci (ACF) in the WT and KO mice treated (+)o r
not treated (2) with AICAR under the high fat diet condition. (D) WT and KO mice fed the high-fat (HF) diet were injected intraperitoneally with various
doses of rapamycin (0.2, 0.4, 0.8 mg/kg) or only with vehicle every other day for 6 weeks. Average values of the BrdU index were decreased in the KO
mice in a dose dependent manner, but not in the WT mice. *p,0.05 compared to non-treated KO mice. (E) Average number of ACF in the WT and KO
mice treated (+) or not treated (2) with rapamycin (0.8 mg/kg) under the high fat diet condition. Each bar represents the mean (with the SEM),
*p,0.05.
Colorectal cancer
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on colonic epithelial proliferation and carcinogenesis under the
high-fat diet. Our experimental condition in which we used
adiponectin-deficient mice fed a high-fat diet may well have
reflected these pathophysiological conditions in humans.
The purpose of our study was to elucidate the role of
adiponectin on colon carcinogenesis, not to elucidate the
mechanism whereby a high-fat diet promotes carcinogenesis.
This mechanism remains unknown. However, we could provide
a possible mechanism underlying the protective roles of
adiponectin in colorectal carcinogenesis promoted by a high-
fat diet We consider that AMPK and mTOR may be novel
therapeutic targets for the prevention of colorectal cancer under
the low levels of plasma adiponectin in an obese population
where the obesity is a result of a Western-style diet with a high
fat content. Our results shed light on a novel mechanism by
which adiponectin might suppress carcinogenesis mediated by a
high-fat diet. Continued investigation to elucidate the precise
mechanisms involved is necessary because of the major clinical
implications.
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